ENDRA Life Sciences (NDRA) Accumulated Expenses (2016 - 2025)

ENDRA Life Sciences (NDRA) has reported Accumulated Expenses for 10 consecutive years, with $448419.0 the latest figure, recorded in Q2 2025.

• On a quarterly basis, Accumulated Expenses rose 37.55% year-over-year to $448419.0 in Q2 2025; TTM through Jun 2025 was $448419.0, a 37.55% increase from a year earlier, with the FY2024 full-year figure at $508293.0, up 238.2% from the prior year.
• Accumulated Expenses was $448419.0 for Q2 2025 at ENDRA Life Sciences, up from $439688.0 in the prior quarter.
• Over five years, Accumulated Expenses peaked at $1.5 million in Q1 2021 and troughed at $60638.0 in Q4 2022.
• A 5-year average of $389194.9 and a median of $216426.0 in 2023 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses plunged 90.01% in 2022 and soared 238.2% in 2024, its largest moves.
• Over 5 years, Accumulated Expenses stood at $101459.0 in 2021, then sank by 40.23% to $60638.0 in 2022, then soared by 147.85% to $150293.0 in 2023, then soared by 238.2% to $508293.0 in 2024, then slipped by 11.78% to $448419.0 in 2025.
• The last three Accumulated Expenses figures came in at $448419.0 (Q2 2025), $439688.0 (Q1 2025), and $508293.0 (Q4 2024), per Business Quant data.